Friday, March 15, 2024 12:16:52 PM
Recent RNAZ News
- TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors • GlobeNewswire Inc. • 04/15/2024 01:00:00 PM
- TransCode Therapeutics Reports 2023 Results; Provides Business Update • GlobeNewswire Inc. • 04/03/2024 01:10:00 PM
- TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer • GlobeNewswire Inc. • 03/28/2024 12:30:00 PM
- TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment • GlobeNewswire Inc. • 03/11/2024 01:00:00 PM
- TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress • GlobeNewswire Inc. • 03/06/2024 09:15:00 PM
- TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 09:00:30 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:12:31 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:33:08 PM
- Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market • GlobeNewswire Inc. • 01/31/2024 09:05:00 PM
- TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer • GlobeNewswire Inc. • 01/29/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:45:50 PM
- TransCode Therapeutics Announces Closing of $7.25 Million Public Offering • GlobeNewswire Inc. • 01/22/2024 09:45:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 01/20/2024 02:57:15 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/19/2024 05:15:08 AM
- TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering • GlobeNewswire Inc. • 01/18/2024 06:27:45 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/18/2024 03:39:59 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/17/2024 12:06:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:01:22 PM
- TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO • GlobeNewswire Inc. • 01/12/2024 09:05:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/11/2024 01:22:19 PM
- TransCode Therapeutics Announces 1-for-40 Reverse Stock Split • GlobeNewswire Inc. • 01/11/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:01:49 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/04/2024 05:41:41 PM
- TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives • GlobeNewswire Inc. • 01/04/2024 01:05:00 PM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM